DelveInsight’s, “Fragile X Syndrome Pipeline Insight 2023” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Fragile X Syndrome pipeline landscape. It covers the Fragile X Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Fragile X Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Fragile X Syndrome Pipeline Report

• DelveInsight’s Fragile X Syndrome pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Fragile X Syndrome treatment.
• The leading companies working in the Fragile X Syndrome Market include Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics, Alcobra Ltd., Seaside Therapeutics, Inc., Marinus Pharmaceuticals, Novartis Pharmaceuticals, Neuren Pharmaceuticals, Hoffmann-La Roche, Healx, Nova Mentis, Lysogene, Actinogen, Prilenia Therapeutics, Confluence Pharmaceuticals, Sentinel Oncology, and others.
• Promising Fragile X Syndrome Pipeline Therapies in the various stages of development include Psilocybin, 1.5 mg, MG01CI, Zatolmilast/ BPN14770, arbaclofen, and others.
• February 2023: Tetra Discovery Partners announced a study of Phase 3 Clinical Trials for Zatolmilast/ BPN14770. This is an open-label extension (OLE) study for subjects completing one of two double-blind clinical trials with BPN14770, Study BPN14770-CNS-301(in adult males) and Study BPN14770-CNS-204 (in adolescent males).
• May 2023: Nova Mentis Life Science Corp announced a study of Phase 2 Clinical Trials for Psilocybin, 1.5 mg. The overall objective of this study is to assess the feasibility of low-dose psilocybin as a therapeutic option for individuals living with FXS and to improve diagnostic parameters of FXS, as well as therapeutic responses with the use of biomarkers.

 

Request a sample and discover the recent advances in Fragile X Syndrome Treatment Drugs @ Fragile X Syndrome Pipeline Report

 

In the Fragile X Syndrome pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Fragile X Syndrome clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Fragile X Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Fragile X Syndrome Overview

Fragile X syndrome (FXS) is a genetic disorder. FXS is caused by changes in a gene that scientists called the fragile X mental retardation 1 (FMR1) gene when it was first discovered. The FMR1 gene usually makes a protein called fragile X mental retardation protein (FMRP).

 

Find out more about Fragile X Syndrome Therapeutics Assessment @ Fragile X Syndrome Preclinical and Discovery Stage Products

 

Fragile X Syndrome Emerging Drugs Profile

• Zatolmilast: Tetra Discovery Partners
• Zygel: Zynerba Pharmaceuticals
• Pridopidine: Prilenia Therapeutics

 

Fragile X Syndrome Pipeline Therapeutics Assessment

There are approx. 20+ key companies which are developing the Fragile X Syndrome therapies. The Fragile X Syndrome companies which have their Fragile X Syndrome drug candidates in the most advanced stage, i.e. Phase III include Zynerba Pharmaceuticals and others.

 

Learn more about the emerging Fragile X Syndrome Pipeline Therapies @ Fragile X Syndrome Clinical Trials Assessment

 

Scope of the Fragile X Syndrome Pipeline Report

• Coverage- Global
• Fragile X Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Fragile X Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Fragile X Syndrome Companies- Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics, Alcobra Ltd., Seaside Therapeutics, Inc., Marinus Pharmaceuticals, Novartis Pharmaceuticals, Neuren Pharmaceuticals, Hoffmann-La Roche, Healx, Nova Mentis, Lysogene, Actinogen, Prilenia Therapeutics, Confluence Pharmaceuticals, Sentinel Oncology, and others.
• Fragile X Syndrome Pipeline Therapies- Psilocybin, 1.5 mg, MG01CI, Zatolmilast/ BPN14770, arbaclofen, and others.

 

Dive deep into rich insights for new drugs for Fragile X Syndrome Treatment, Visit @ Fragile X Syndrome Market Drivers and Barriers, and Future Perspective

 

 

Table of Content

1. Introduction
2. Executive Summary
3. Fragile X Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Fragile X Syndrome– DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Fragile X Syndrome Collaboration Deals
9. Late Stage Products (Phase III)
10. Zatolmilast: Tetra Discovery Partners
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. HLX-0201: Healx
14. Drug profiles in the detailed report…..
15. Preclinical Stage Products
16. Pridopidine: Prilenia Therapeutics
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Fragile X Syndrome Key Companies
20. Fragile X Syndrome Key Products
21. Fragile X Syndrome- Unmet Needs
22. Fragile X Syndrome- Market Drivers and Barriers
23. Fragile X Syndrome- Future Perspectives and Conclusion
24. Fragile X Syndrome Analyst Views
25. Fragile X Syndrome Key Companies
26. Appendix

 

For further information on the Fragile X Syndrome Pipeline therapeutics, reach out to Fragile X Syndrome Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking